ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis (NCT07090330)
A Multicenter, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis
๐ฉบ Plain-English Summary (8th-Grade Level)
This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Who can join: Review the eligibility criteria below.
Location: Oruka Therapeutics Investigative Site โ Fountain Valley, California
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- Oruka Therapeutics Investigative Site โ Fountain Valley, California
- Oruka Therapeutics Investigative Site โ Los Angeles, California
- Oruka Therapeutics Investigative Site โ San Diego, California
- Oruka Therapeutics Investigative Site โ Santa Ana, California
- Oruka Therapeutics Investigative Site โ Santa Monica, California
- Oruka Therapeutics Investigative Site โ Cromwell, Connecticut
- Oruka Therapeutics Investigative Site โ Miami, Florida
- Oruka Therapeutics Investigative Site โ Rolling Meadows, Illinois
- Oruka Therapeutics Investigative Site โ Bowling Green, Kentucky
- Oruka Therapeutics Investigative Site โ Rockville, Maryland
- Oruka Therapeutics Investigative Site โ Boston, Massachusetts
- Oruka Therapeutics Investigative Site โ Detroit, Michigan
- Oruka Therapeutics Investigative Site โ New York, New York
- Oruka Therapeutics Investigative Site โ New York, New York
- Oruka Therapeutics Investigative Site โ Portland, Oregon
- Oruka Therapeutics Investigative Site โ Norfolk, Virginia
- Oruka Therapeutics Investigative Site โ Milwaukee, Wisconsin
- Oruka Therapeutics Investigative Site โ Edmonton, Alberta
- Oruka Therapeutics Investigative Site โ Edmonton, Alberta
- Oruka Therapeutics Investigative Site โ Surrey, British Columbia
- Oruka Therapeutics Investigative Site โ Hamilton, Ontario
- Oruka Therapeutics Investigative Site โ London, Ontario
- Oruka Therapeutics Investigative Site โ Markham, Ontario
- Oruka Therapeutics Investigative Site โ Peterborough, Ontario
- Oruka Therapeutics Investigative Site โ Toronto, Ontario
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Plaque Psoriasis
- A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis โ Phoenix, Arizona
- Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis โ Phoenix, Arizona
- A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis โ Birmingham, Alabama
- Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects โ Rogers, Arkansas
- Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis โ Birmingham, Alabama
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) โ Phoenix, Arizona
Explore by condition: All Plaque Psoriasis clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.